This article has been updated from a previous version, which incorrectly identified Asuragen as an ABI subsidiary. The details of ABI's acquisition of Ambion have also been corrected.
NEW YORK (GenomeWeb News) — Illumina today said it has certified Asuragen as a gene expression profiling services provider for its Human-6 Expression BeadChip.
Illumina has also certified DeCode Genetics to use its Infinium BeadChip genotyping platform.
Asuragen, which specializes in RNA, microRNA, and gene-expression and array products and services, will use the Human-6 BeadChip for profiling services to support clinical research studies, pharmacogenomics, and biomarker discovery.
The company is a spin-off of Ambion's diagnostics and services division that was created in 2006 when ABI purchased Ambion’s research products division for $273 million in cash.
For Decode, to become a certified service provider for Illumina’s Infinium tool, the company passed a two-phase process that included data generation and data certification, and underwent on-site audits of processes and facilities.
DeCode will use the BeadChip platform in conjunction with its Disease Miner software and other disease-related IP to develop DNA-based diagnostics and to offer expanded contract genotyping services to its customers.
DeCode’s genotyping facility is located in its headquarters in Reykjavik, Iceland.
DeCode and Illumina last May signed an agreement to develop and market molecular diagnostics for type II diabetes, breast cancer and heart attack.